康方生物免疫+TKI一线治疗HCC获批 派安普利单抗疗法第5项适应症国内上市

港美通
Dec 26, 2025

12月26日,据 康方生物 公众号,公司自主研发的差异化PD-1单抗安尼可·(派安普利单抗注射液)联合安罗替尼,用于一线治疗晚期肝细胞癌(HCC)的新适应症,已正式获得中国国家药品监督管理局(NMPA)批准,为中国庞大的肝癌患者群体提供了高效、创新的“免疫+靶向”一线标准治疗选择。据悉,此次一线肝癌适应症的获批,是派安普利单抗在中国收获的第5项适应症。此前,派安普利单抗一线治疗鳞状非小细胞肺癌、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10